Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bower

Showing results (71-80 of 252) with videos related to

Pageof 26
Sort By:
Immunotherapy|February 5, 2014
The use of monoclonal antibodies to treat Castleman's diseaseRebecca C Robey, Salvinia Mletzko, Charlotte Colley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 21, 2014
Diagnostic criteria schemes for multicentric Castleman disease in 75 casesMark Bower, Alessia Dalla Pria, Christopher Coyle, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2015
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapyAlessia Dalla Pria, Maggie Bendle, Ramya Ramaswami, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2025
Management of KSHV/HHV8-Positive Multicentric Castleman Disease Concurrent With Other KSHV/HHV8-Positive Disorders: An Emergent Challenge in PLWHAntonino Carbone, Emanuela Vaccher, Annunziata Gloghini, et al.
AIDS (London, England)|March 2, 2002
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphomaTom Powles, Nesrina Imami, Mark Nelson, et al.
British Journal of Cancer|August 28, 2015
The exclusion of people living with HIV (PLWH) from clinical trials in lymphomaSerena Venturelli, Alessia Dalla Pria, Katrina Stegmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2005
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining eventsJustin Stebbing, Laura Waters, Sundhiya Mandalia, et al.
Journal of the National Cancer Institute|August 3, 2006
Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphomaMark Bower, Tom Powles, Mark Nelson, et al.
Lancet (London, England)|May 9, 2006
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapyJustin Stebbing, Adam Sanitt, Mark Nelson, et al.
The Lancet. HIV|September 9, 2023
Lymphomas included in the AIDS case definition: an update 30 years laterEmanuela Vaccher, Amy Chadburn, Annunziata Gloghini, et al.
Pageof 26

Showing results (71-80 of 252) with videos related to

Sort By:
Pageof 26
Immunotherapy|February 5, 2014
The use of monoclonal antibodies to treat Castleman's diseaseRebecca C Robey, Salvinia Mletzko, Charlotte Colley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 21, 2014
Diagnostic criteria schemes for multicentric Castleman disease in 75 casesMark Bower, Alessia Dalla Pria, Christopher Coyle, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2015
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapyAlessia Dalla Pria, Maggie Bendle, Ramya Ramaswami, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2025
Management of KSHV/HHV8-Positive Multicentric Castleman Disease Concurrent With Other KSHV/HHV8-Positive Disorders: An Emergent Challenge in PLWHAntonino Carbone, Emanuela Vaccher, Annunziata Gloghini, et al.
AIDS (London, England)|March 2, 2002
Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphomaTom Powles, Nesrina Imami, Mark Nelson, et al.
British Journal of Cancer|August 28, 2015
The exclusion of people living with HIV (PLWH) from clinical trials in lymphomaSerena Venturelli, Alessia Dalla Pria, Katrina Stegmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2005
Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining eventsJustin Stebbing, Laura Waters, Sundhiya Mandalia, et al.
Journal of the National Cancer Institute|August 3, 2006
Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphomaMark Bower, Tom Powles, Mark Nelson, et al.
Lancet (London, England)|May 9, 2006
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapyJustin Stebbing, Adam Sanitt, Mark Nelson, et al.
The Lancet. HIV|September 9, 2023
Lymphomas included in the AIDS case definition: an update 30 years laterEmanuela Vaccher, Amy Chadburn, Annunziata Gloghini, et al.
Pageof 26